AUTHORS
Carmine Deluca, BA, Michael Beyer, BS2, Jay R Hydren, PhD3, Jennifer M Ahlstrom, BA4, Hannah Loosle5, Dalton Bean6, Dana Wills7, Paula Cramer, MD8, Toby A. Eyre, MBChB, DipMedEd, MRCP, MD9, George A Follows, MA, BM, BCh, PhD, FRCP, FRCPath10, Jennifer A. Woyach, MD11
AFFILIATIONS
1 PVI, PeerView Institute for Medical Education, New York, New York, United States
2 PVI, PeerView Institute for Medical Education, New York, New York, United States
3 HealthTree Foundation, Salt Lake City, Utah, United States
4 HealthTree Foundation, South Jordan, United States
5 HealthTree Foundation, South Jordan, United States
6 HealthTree Foundation, South Jordan, United States
7 PVI, PeerView Institute for Medical Education, New York, New York, United States
8 University Hospital Cologne, Cologne, Germany
9 Oxford University Hospitals, Oxford, United Kingdom
10 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
11 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Background: Targeted therapy delivered as time-limited or continuous treatment has largely supplanted chemoimmunotherapy in the management of chronic lymphocytic leukemia (CLL), including in treatment-naive and relapsed/refractory (R/R) disease, as well as in poor or favorable prognostic settings. Increasingly, patient preferences are informing the choice of continuous or time-limited treatment as driven by factors such as regimen complexity, need for clinic visits, caregiver support, and desire for time off treatment (Eichhorst B et al. Hemasphere. 2026;10:e70403.; Davids MS et al. Blood Cancer J. 2026;16:19). To build on a prior survey of patients with R/R CLL (N=219; DeLuca C, et al. Blood. 2025;146:6428) we further assessed contemporary patient preferences for CLL therapy in a global survey and determined how exposure to patient views on modern care influenced clinical decision-making in CLL.
Methods: We conducted a global online survey of an academic-enriched, highly engaged cohort of patients with CLL and their caregivers (N=73 at data cut-off) in 2026 through the HealthTree Foundation for CLL to characterize patient-reported priorities and concerns influencing contemporary CLL treatment decisions. These findings were integrated into a series of live and enduring educational initiatives aimed at hematologist-oncologists in the US and Europe (N = 815 clinicians participating to date; pre- and post-assessment completers analyzed below). Clinicians completed pre- and post-assessments to evaluate changes in skills and attitudes toward incorporating patient preferences into CLL care.
Results: Respondents to the patient survey had a median age of 67 years (range, 39–87) and were 58% male; treatment status spanned the disease course (43% watch-and-wait, 32% receiving or completing first-line therapy, and 25% treated in later lines). Quality of life—maintaining daily activities and overall well-being—was ranked as the top treatment consideration by 80% of patients, while 43% identified durable, long-term disease control as the single most important factor guiding their treatment decisions. Only 51% reported a provider-initiated discussion of continuous versus time-limited therapy, leaving nearly half without an explicit treatment-duration conversation. Among the 34 patient respondents addressing time-limited-therapy challenges, uncertainty about remission duration was the leading concern (65%). After clinicians were exposed to education incorporating patient survey results, the proportion reporting they would frequently or always explain the logistical implications of continuous versus fixed-duration treatment during pre-therapy counseling increased from 59% to 89% (pre n=595, post n=513; P<.05, chi-square), while those reporting they would routinely incorporate patient preferences regarding treatment duration and route of administration into clinical decisions increased from 63% to 87% (P<.05). Qualitative analyses of feedback submitted by clinicians revealed a greater willingness to include patient perspectives when deciding on treatment before each new line of therapy, and greater openness to discussing concerns over treatment-related toxicity.
Conclusion: In this cross-sectional survey of a self-selected, digitally engaged registry cohort, patients with CLL/SLL prioritized quality of life and durable disease control, with uncertainty about remission duration emerging as a leading concern regarding fixed-duration therapy. Integrating patient-reported priorities into clinician education was associated with increased intention to discuss treatment logistics and to incorporate patient preferences into therapy selection. These findings suggest that systematically surfacing patient perspectives can strengthen shared decision-making in CLL/SLL care. Prospective evaluation of whether these reported intentions translate into real-world practice change is warranted.
DISCLOSURES
Carmine Deluca, BA: No relevant conflicts of interest to declare.